For the final yr, a small California startup has been making extraordinary claims in regards to the skill of its know-how to probably deal with Duchenne muscular dystrophy — and possibly a slew of different genetic illnesses, too.
The corporate, Sonothera, doesn’t but have medical information. However it’s introduced information in animals so beautiful that different consultants can’t fairly wrap their minds round it.
“I discover it onerous to imagine,” stated Eric Olson, molecular biology chair at UT-Southwestern Medical Heart. “It appears a bit too good to be true,” stated Jeffrey Chamberlain, a longtime Duchenne gene remedy professional on the College of Washington.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
View All Plans
